INT308567

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.32
First Reported 2010
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 1
Total Number 3
Disease Relevance 2.48
Pain Relevance 0.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (VPS45) vesicle-mediated transport (VPS45) Golgi apparatus (VPS45)
intracellular (VPS45) molecular_function (VPS45) cellular_component (VPS45)
Anatomy Link Frequency
endothelial cell 1
VPS45 (Homo sapiens)
Pain Link Frequency Relevance Heat
cva 9 98.44 Very High Very High Very High
Pain 9 5.00 Very Low Very Low Very Low
antagonist 9 5.00 Very Low Very Low Very Low
cINOD 6 5.00 Very Low Very Low Very Low
Calcium channel 6 5.00 Very Low Very Low Very Low
COX2 3 5.00 Very Low Very Low Very Low
iatrogenic 3 5.00 Very Low Very Low Very Low
alcohol 3 5.00 Very Low Very Low Very Low
beta blocker 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Nephrotoxicity 3 99.00 Very High Very High Very High
Thrombosis 3 98.68 Very High Very High Very High
Hemorrhage 3 98.44 Very High Very High Very High
Cardiovascular Disease 24 97.36 Very High Very High Very High
Hypertension 204 96.36 Very High Very High Very High
Metastasis 3 87.88 High High
Solid Tumor 6 78.88 Quite High
Cancer 84 75.56 Quite High
Disease 6 75.56 Quite High
Renal Cancer 9 71.32 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Some evidence suggests that two effects of VSP inhibition on the systemic vasculature contribute to BP elevation: 1) increased vascular tone because of decreased nitric oxide production and 2) increased peripheral resistance because of endothelial cell damage and dysfunction (24–27).
VSP Neg (inhibition) Binding (inhibition) of in endothelial cell
1) Confidence 0.32 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2864290 Disease Relevance 0.78 Pain Relevance 0.03
Nevertheless, control of BP is important for patients receiving VSP inhibitor therapy for the following five reasons:Serious adverse events have been associated with unmanaged hypertension (1–3,5,34), and these could be prevented with control of BP before and early in the course of VSP inhibitor therapy.These agents can cause dramatic increases in BP from pretreatment measurements (as high as 29 mmHg systolic and 27 mmHg diastolic in one prospective clinical investigation) (35) during the first week of treatment (35,36), and currently, it cannot be predicted which patients will have this magnitude of BP elevation.Although minimalist approaches to hypertension for patients with incurable disease might be favored in certain circumstances, management of comorbidities, including hypertension, could improve overall survival.
VSP inhibitor Binding (therapy) of associated with hypertension and disease
2) Confidence 0.32 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2864290 Disease Relevance 0.65 Pain Relevance 0
Hemorrhage, thrombosis, nephrotoxicity, and cardiac toxic effects are also increasingly recognized adverse events of VSP inhibitors, but because BP elevations are more common and easier to address, this Commentary focuses on BP management.


VSP Binding (recognized) of associated with nephrotoxicity, cva and thrombosis
3) Confidence 0.30 Published 2010 Journal JNCI Journal of the National Cancer Institute Section Body Doc Link PMC2864290 Disease Relevance 1.05 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox